28 results
8-K
ADAP
Adaptimmune Therapeutics Plc
28 Apr 20
Other Events
8:26am
and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma.
The press release is furnished as Exhibit 99.1
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
28 Apr 20
Other Events
8:26am
and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma.
About Adaptimmune
Adaptimmune is a clinical-stage
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Dec 23
Other Events
7:13am
and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma.
About Afami-cel
Afami-cel is an engineered T-cell receptor
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
liposarcoma (MRCLS). The product was granted Orphan Drug Designation, for the treatment of soft tissue sarcomas, and Regenerative Medicine Advanced Therapy
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Aug 20
Adaptimmune Reports Q2 Financial Results and Business Update
7:37am
with advanced sarcoma, along with the previously granted Orphan Drug Designation (ODD) in Europe, as well as the FDA’s ODD and Regenerative Medicine
8-K
EX-99.1
dvki5 g4pf8lcpahrvh
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
fepvb65u68qi
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
3td1 2dgdj4a0o1gccs8
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
2g028 unn0y
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am